Reports received by FDA, by month

April 2007: adverse event reports received by FDA

18,563 drug reports (FAERS) and 12,822 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

18,563
drug reports received: 21,150 a year earlier; 19,830
monthly average, preceding 12 months: -6.4% against the average; 12,822
device reports received: 8,270 a year earlier

FDA received 18,563 drug adverse event reports in April 2007, against 21,150 in the same month a year earlier and a monthly average of 19,830 over the preceding 12 months. The MAUDE device database received 12,822 reports that month (8,270 a year earlier).

The drugs listed most often as suspect products were Nexium (824), Cymbalta (760) and Lunesta (614), and the reactions recorded most often were nausea (822), drug ineffective (799) and dyspnoea (678).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Nexium (23.7× its average), Zelnorm (16.7× its average) and Ultram (7.7× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to April 2007

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Nexium	824	4.4%
Cymbalta	760	4.1%
Lunesta	614	3.3%
Remicade	354	1.9%
Avonex	341	1.8%
Enbrel	284	1.5%
Bextra	272	1.5%
Zelnorm	272	1.5%
Celebrex	237	1.3%
Geodon	231	1.2%
Forteo	202	1.1%
Levemir	196	1.1%
Zometa	195	1.1%
Chantix	195	1.1%
Lyrica	190	1%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Nexium	824	23.7×
Zelnorm	272	16.7×
Ultram	94	7.7×
Tamiflu	128	6.7×
Bevacizumab	120	6.1×
Zofran	102	5.4×
Geodon	231	5.3×
Lucentis	52	5×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Nauseafeeling sick	822	4.4%
Drug ineffectivethe medicine did not work as expected	799	4.3%
Dyspnoeashortness of breath	678	3.7%
Vomitingbeing sick	630	3.4%
Diarrhoealoose or frequent stools	589	3.2%
Dizzinesslight-headedness or unsteadiness	588	3.2%
Headachehead pain	564	3%
Pyrexiafever	526	2.8%
Fatiguetiredness	494	2.7%
Insomniadifficulty sleeping	488	2.6%
Astheniaweakness or lack of energy	452	2.4%
Falla fall	426	2.3%
Myocardial infarctionheart attack	410	2.2%
Deaththe patient died; cause not stated by this term	397	2.1%
Depressionlow mood	396	2.1%

Devices named most often

Brand	Reports	Share of device reports
Freestyle Flash	1,592	12.4%
Freestyle	622	4.9%
Accu-Chek Comfort Curve Test Strips	325	2.5%
Cypher Sirolimus-Eluting Coronary Stent	213	1.7%
M Series	186	1.5%
Starclose Vascular Closure System	185	1.4%
Taxus Express2 Paclitaxel-Eluting Coronary Stent System	169	1.3%
Coaguchek S System	159	1.2%
Architect I2000sr Analyzer	149	1.2%
Programming Software	137	1.1%

Questions about April 2007

How many adverse event reports did FDA receive in April 2007?

18,563 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 12,822 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 21,150 drug reports.

Which drugs were listed most often?

Nexium (824), Cymbalta (760), Lunesta (614), Remicade (354) and Avonex (341).

Which reactions were recorded most often?

nausea (822), drug ineffective (799), dyspnoea (678), vomiting (630) and diarrhoea (589).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.